Frequently Asked Questions
1What does Caladrius do?
Caladrius Biosciences, Inc. is a clinical stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications using CD34 cell therapy and autoimmune diseases using T regulatory cell therapy.
2How many employees does Caladrius Biosciences have?
As of June 1, 2018, the company has 24 full-time employees.
3Where can I find Caladrius Biosciences’ latest investor presentation?
The company’s most recent investor presentation is available in the “Investors” section on the company’s website.
4What is Caladrius’ ticker symbol, exchange and CUSIP?
The Company’s common stock is traded on NASDAQ, ticker symbol CLBS. The CUSIP for the common stock is 128058203.
5What is Caladrius’ fiscal year?
Caladrius’ fiscal year ends on December 31.
6Where are Caladrius Biosciences’ headquarters?
Caladrius Biosciences Headquarters 110 Allen Road, 2nd Floor, Basking Ridge, NJ 07920 Tel: (908) 842-0100
7Who is Caladrius’ IR contact?
Caladrius Biosciences, Inc.
John D. Menditto
Investor Relations & Corporate Communications
8What is Caladrius’ Financial Conflict of Interest Policy?
You can view the Company’s Financial Conflict of Interest Policy by clicking here.
9Who are Caladrius’ auditor and corporate legal counsel?
10Who is Caladrius’ transfer agent?
Caladrius’ transfer agent is Continental Stock Transfer & Trust Company (www.continentalstock.com) 17 Battery Place, 8th Floor New York NY 10004 Tel: (212) 509-4000
11Who do I contact about replacement of stock certificates?
To replace lost stock certificates, please contact Caladrius Biosciences’ transfer agent
12Who should shareholders notify of a change in address?
To change your address, please contact Caladrius Biosciences’ transfer agent.
13What financial analysts cover Caladrius Biosciences?
Please refer to the “Analyst Coverage” section of the “Investors” section.
14Can I buy Caladrius Biosciences stock directly from the company?
Caladrius does not offer a direct stock purchase plan. Shares of the company can be purchased through a brokerage company.
15Does Caladrius Biosciences issue dividends on its common stock?
Caladrius Biosciences has never declared or paid cash dividends. The company intends to retain any future earnings for the operation and expansion of its business and does not anticipate paying any cash dividends in the foreseeable future.
16When is Caladrius Biosciences’ Annual Meeting of Stockholders?
Specific information about this year’s Annual Shareholder Meeting can be found in this year’s proxy statement. “SEC Filings” section in the “Investors” section on the company’s website.
17What should I do if I have a question that is not answered here?
Please submit your question using the form in the “Contact” section.
18Where can I find more information on the reverse stock split effective July 27, 2016?
The reverse stock split is announced at http://www.caladrius.com/press-release/1-for-10-reverse-split/ . Additional information about the reverse stock split can be found in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission (SEC) on May 10, 2016, a copy of which is available at www.sec.gov or at the company’s website at www.caladrius.com. More detailed information regarding this reverse stock split can be found in the Company’s Form 8-K filed with the SEC on July 27, 2016.